These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 35217796)

  • 1. Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects.
    Holze F; Ley L; Müller F; Becker AM; Straumann I; Vizeli P; Kuehne SS; Roder MA; Duthaler U; Kolaczynska KE; Varghese N; Eckert A; Liechti ME
    Neuropsychopharmacology; 2022 May; 47(6):1180-1187. PubMed ID: 35217796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects.
    Holze F; Vizeli P; Ley L; Müller F; Dolder P; Stocker M; Duthaler U; Varghese N; Eckert A; Borgwardt S; Liechti ME
    Neuropsychopharmacology; 2021 Feb; 46(3):537-544. PubMed ID: 33059356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants.
    Ley L; Holze F; Arikci D; Becker AM; Straumann I; Klaiber A; Coviello F; Dierbach S; Thomann J; Duthaler U; Luethi D; Varghese N; Eckert A; Liechti ME
    Neuropsychopharmacology; 2023 Oct; 48(11):1659-1667. PubMed ID: 37231080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects.
    Dolder PC; Schmid Y; Steuer AE; Kraemer T; Rentsch KM; Hammann F; Liechti ME
    Clin Pharmacokinet; 2017 Oct; 56(10):1219-1230. PubMed ID: 28197931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute effects of MDMA and LSD co-administration in a double-blind placebo-controlled study in healthy participants.
    Straumann I; Ley L; Holze F; Becker AM; Klaiber A; Wey K; Duthaler U; Varghese N; Eckert A; Liechti ME
    Neuropsychopharmacology; 2023 Dec; 48(13):1840-1848. PubMed ID: 37258715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ketanserin Reverses the Acute Response to LSD in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Participants.
    Becker AM; Klaiber A; Holze F; Istampoulouoglou I; Duthaler U; Varghese N; Eckert A; Liechti ME
    Int J Neuropsychopharmacol; 2023 Feb; 26(2):97-106. PubMed ID: 36342343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects.
    Holze F; Vizeli P; Müller F; Ley L; Duerig R; Varghese N; Eckert A; Borgwardt S; Liechti ME
    Neuropsychopharmacology; 2020 Feb; 45(3):462-471. PubMed ID: 31733631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety pharmacology of acute LSD administration in healthy subjects.
    Holze F; Caluori TV; Vizeli P; Liechti ME
    Psychopharmacology (Berl); 2022 Jun; 239(6):1893-1905. PubMed ID: 34515824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects.
    Schmid Y; Enzler F; Gasser P; Grouzmann E; Preller KH; Vollenweider FX; Brenneisen R; Müller F; Borgwardt S; Liechti ME
    Biol Psychiatry; 2015 Oct; 78(8):544-53. PubMed ID: 25575620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants.
    Holze F; Liechti ME; Hutten NRPW; Mason NL; Dolder PC; Theunissen EL; Duthaler U; Feilding A; Ramaekers JG; Kuypers KPC
    Clin Pharmacol Ther; 2021 Mar; 109(3):658-666. PubMed ID: 32975835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response.
    Calder AE; Rausch B; Liechti ME; Holze F; Hasler G
    J Psychopharmacol; 2024 Oct; 38(10):873-886. PubMed ID: 39302087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults.
    Murray CH; Tare I; Perry CM; Malina M; Lee R; de Wit H
    Psychopharmacology (Berl); 2022 Jun; 239(6):1735-1747. PubMed ID: 34613430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers.
    Bershad AK; Schepers ST; Bremmer MP; Lee R; de Wit H
    Biol Psychiatry; 2019 Nov; 86(10):792-800. PubMed ID: 31331617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addressing the Current Knowledge and Gaps in Research Surrounding Lysergic Acid Diethylamide (LSD), Psilocybin, and Psilocin in Rodent Models.
    Ezeaka UC; Kim HJJ; Laprairie RB
    Curr Top Med Chem; 2023; 23(23):2232-2241. PubMed ID: 37409550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Greater subjective effects of a low dose of LSD in participants with depressed mood.
    Molla H; Lee R; Tare I; de Wit H
    Neuropsychopharmacology; 2024 Apr; 49(5):774-781. PubMed ID: 38042914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations of consciousness and mystical-type experiences after acute LSD in humans.
    Liechti ME; Dolder PC; Schmid Y
    Psychopharmacology (Berl); 2017 May; 234(9-10):1499-1510. PubMed ID: 27714429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers.
    Ramaekers JG; Hutten N; Mason NL; Dolder P; Theunissen EL; Holze F; Liechti ME; Feilding A; Kuypers KP
    J Psychopharmacol; 2021 Apr; 35(4):398-405. PubMed ID: 32842825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants.
    Müller F; Kraus E; Holze F; Becker A; Ley L; Schmid Y; Vizeli P; Liechti ME; Borgwardt S
    Psychopharmacology (Berl); 2022 Jun; 239(6):1933-1943. PubMed ID: 35076721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability, pharmacokinetics, and subjective effects of 50, 75, and 100 µg LSD in healthy participants within a novel intervention paradigm: A proof-of-concept study.
    Family N; Hendricks PS; Williams LT; Luke D; Krediet E; Maillet EL; Raz S
    J Psychopharmacol; 2022 Mar; 36(3):321-336. PubMed ID: 35253516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute Effects of Lysergic Acid Diethylamide on Circulating Steroid Levels in Healthy Subjects.
    Strajhar P; Schmid Y; Liakoni E; Dolder PC; Rentsch KM; Kratschmar DV; Odermatt A; Liechti ME
    J Neuroendocrinol; 2016 Mar; 28(3):12374. PubMed ID: 26849997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.